BRAF and neoplasm: In contrast to previous reports in a BRAF mutated cell line [72], ERK-I monotherapy failed to control tumor growth at a dosing of 12.5 mg/kg bid whereas the combination of CET with SCH772984, albeit it did not reach our criteria for stable disease, somewhat controlled tumor growth, but was unable to induce tumor shrinkage (Fig. 9e).